{"filing":{"accession_number":"0001213900-26-096235","cik":"0002075320","ticker":"PLYX","company_name":"Polaryx Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-01","report_date":"2026-09-01","primary_document":"ea0303928-8k_polaryx.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2075320/000121390026096235/ea0303928-8k_polaryx.htm"},"events":[{"id":31015,"run_id":28444,"accession_number":"0001213900-26-096235","anchor_item_number":"7.01","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Polaryx Therapeutics appointed Will Charlton, M.D., M.A.S. as Chief Medical Officer, effective September 1, 2026. Dr. Charlton brings extensive experience in rare disease and pediatric drug development and will lead the company's planned SOTERIA Phase 2 trial initiation in Q4 2026, making this a material appointment for a clinical-stage biotech company on the eve of a pivotal trial launch.","company_name":"Polaryx Therapeutics, Inc.","ticker":"PLYX","filing_date":"2026-09-01","form":"8-K","submitted_at":null,"items":[{"id":33784,"accession_number":"0001213900-26-096235","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Will Charlton, M.D., M.A.S. as Chief Medical Officer of Polaryx Therapeutics, effective September 1, 2026. The press release emphasizes his extensive experience in rare disease and pediatric drug development, his prior CMO roles, and his critical importance to leading the company's SOTERIA Phase 2 trial initiation planned for Q4 2026. This is a material executive appointment at a clinical-stage biotech company on the eve of a pivotal clinical trial launch.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T20:34:07.842436+00:00","company_name":"","ticker":null,"filing_date":""},{"id":33786,"accession_number":"0001213900-26-096235","item_number":"8.01","item_title":"Other Events.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Will Charlton, M.D., M.A.S. as Chief Medical Officer of Polaryx Therapeutics, effective September 1, 2026. This is a clear executive appointment of a named officer to a senior leadership role. The press release emphasizes Dr. Charlton's extensive experience in rare disease clinical development and his critical role leading the company's planned SOTERIA Phase 2 trial initiation in Q4 2026, making this material to investors assessing the company's clinical execution capabilities.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T20:34:07.842436+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33784,"accession_number":"0001213900-26-096235","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Will Charlton, M.D., M.A.S. as Chief Medical Officer of Polaryx Therapeutics, effective September 1, 2026. The press release emphasizes his extensive experience in rare disease and pediatric drug development, his prior CMO roles, and his critical importance to leading the company's SOTERIA Phase 2 trial initiation planned for Q4 2026. This is a material executive appointment at a clinical-stage biotech company on the eve of a pivotal clinical trial launch.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T20:34:07.842436+00:00","company_name":"Polaryx Therapeutics, Inc.","ticker":"PLYX","filing_date":"2026-09-01"},{"id":33786,"accession_number":"0001213900-26-096235","item_number":"8.01","item_title":"Other Events.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Will Charlton, M.D., M.A.S. as Chief Medical Officer of Polaryx Therapeutics, effective September 1, 2026. This is a clear executive appointment of a named officer to a senior leadership role. The press release emphasizes Dr. Charlton's extensive experience in rare disease clinical development and his critical role leading the company's planned SOTERIA Phase 2 trial initiation in Q4 2026, making this material to investors assessing the company's clinical execution capabilities.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T20:34:07.842436+00:00","company_name":"Polaryx Therapeutics, Inc.","ticker":"PLYX","filing_date":"2026-09-01"}]}